Friday, August 19, 2016

MannKind Corp. (MNKD) Relaunches Groundbreaking Inhalable Insulin Afrezza®, Promotes New Copay System

With over 29 million Americans living with diabetes, and more than 86 million with prediabetes, this disease is the seventh leading cause of death and swallows approximately 20% of nationwide healthcare spending, according to Centers for Disease Control and Prevention (CDC) statistics (http://nnw.fm/uUEx3). Healthcare officials, patients and doctors alike are always actively searching for new therapies or innovative yet affordable treatments to combat this disease.

This is where leading biopharmaceutical company MannKind Corporation (NASDAQ: MNKD) and its groundbreaking inhalable insulin product Afrezza® come in. Touted as the first successful insulin inhaler on the U.S. market, Afrezza is a fast-acting inhalable insulin powder designed to be used in conjunction with regular type 1 and 2 diabetes treatments to help lower post-meal blood sugar spikes.

Beginning in July, MannKind relaunched Afrezza Inhalation Powder on the domestic market under its own branding, and the treatment is now available with major wholesalers, as well as by prescription in any retail pharmacy.

Leveraging its two-year experience in patient selection and copayment, the company has also announced several programs to promote patients’ access to Afrezza therapy. These include:

Enhanced copay assistance designed to lower insured patients’ out-of-pocket cost to $15 per month
Patient reimbursement support program, MannKind Cares
Bureau to educate and inform healthcare providers about the benefits of Afrezza
New titration pack that allows patients new to Afrezza more flexibility in adjusting their daily dosage
The new programs will join MannKind’s national salesforce, all of whom have extensive experience with diabetes and Afrezza, in its efforts to help enhance and streamline patients’ and providers’ experience with this key therapy. The company is committed to ensuring the treatment remains available to all diabetes patients in the U.S., without any disruption in supply.

The July relaunch came after the company released six more analyses of the pre-meal treatment, demonstrating a faster onset and shorter duration of action than with mealtime fast-acting insulin treatments. The findings, presented at the 76th scientific session of the American Diabetes Association, show that, compared to Eli Lilly and Company’s (NYSE: LLY) insulin lispro injection, Afrezza has a 50% faster onset and a 2-3-hour shorter duration of action.

The data supports the use of this therapy for rapidly controlling high glucose levels, according to the chief medical officer of MannKind, Raymond W. Urbanski, MD, PhD. Unlike injectable insulin, which risks causing hypoglycemia after a meal if dosed incorrectly, Afrezza works in the body more rapidly and leaves the bloodstream faster, offering an ideal balance between glucose control and a lower risk of hypoglycemia.

To find out more about MannKind Corp. and its innovative Afrezza Inhalation Powder insulin, visit www.MannkindCorp.com


About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html